Welcome to our dedicated page for BIOLASE news (Ticker: BIOL), a resource for investors and traders seeking the latest updates and insights on BIOLASE stock.
BIOLASE Inc. (BIOL) pioneers advanced laser solutions transforming dental care through minimally invasive technologies. This dedicated news hub provides investors and dental professionals with essential updates on product innovations, financial performance, and clinical developments.
Access real-time announcements including earnings reports, FDA clearances, partnership agreements, and technological breakthroughs. Our curated collection ensures transparent access to material events shaping BIOLASE's position in the $7B dental laser market.
Key updates cover regulatory milestones, patent filings, clinical trial results, and executive commentary. Discover how BIOLASE's Waterlase technology and Epic X platform continue redefining standards in laser dentistry through reduced recovery times and enhanced precision.
Bookmark this page for structured access to verified corporate communications. Monitor BIOLASE's progress in expanding global adoption of dental lasers while maintaining compliance with SEC disclosure requirements and medical device regulations.
BIOLASE, a leader in dental lasers, reported a 24% revenue increase to $48.5 million for 2022. U.S. laser sales surged by 39%, contributing significantly to this growth. The company's consumable sales grew by 25%, with 84% of U.S. Waterlase sales coming from new customers. Despite the positive results, gross margin decreased to 33% and operating losses widened to $25.3 million, up 54% from 2021. Looking forward, BIOLASE anticipates at least 25% revenue growth in 2023 and aims for positive adjusted EBITDA. The company ended 2022 with $4.2 million in cash, boosted by a January equity raise of $9 million.
BIOLASE, Inc. announced its annual Tequila & Tongue Ties Conference set for April 21-22, 2023, in Scottsdale, AZ. The event aims to educate dental professionals about tethered oral tissues (TOTs) impacting many newborns. Key opinion leaders will share insights on tongue-tie treatments and the use of the company's Waterlase all-tissue laser. The conference will provide hands-on experience and discussions on practice management. BIOLASE emphasizes its commitment to resolving dental issues to enhance patient care.
BIOLASE, Inc. (NASDAQ: BIOL) will release its fourth quarter and full year 2022 financial results on March 28, 2023, after U.S. market close. A conference call and webcast will follow at 4:30 p.m. ET to discuss these results and related corporate developments. Investors can join the call by dialing 888-506-0062 from the U.S. or +1 973-528-0011 internationally, using earnings code 121864. An archived version of the call will be available on the BIOLASE Investor Relations Page along with a phone replay. BIOLASE is a leader in dental lasers, offering over 302 patented technologies for enhanced dental procedures.
BIOLASE (NASDAQ: BIOL) announces the launch of its second podcast season, Advancing Dentistry, following positive feedback from the dental community. The podcast aims to educate listeners about laser technology in dentistry, specifically the impact of Waterlase technology on patient outcomes. Hosted by Dr. Stephen John, season 2 will feature discussions with dental experts on various trending topics. The podcast will be available on Spotify and Apple Podcasts. The initiative reflects BIOLASE's commitment to advancing dentistry through education and innovation.
FAQ
What is the current stock price of BIOLASE (BIOL)?
What is the market cap of BIOLASE (BIOL)?
